Subscribe for the Newsletter

Mobile Navigation

Company Info

Monopteros Therapeutics

Monopteros Therapeutics

Drug Discovery & Development

Overview

Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset, MPT-0118, is undergoing a Phase 1/1b clinical trial to investigate reprogramming regulatory T cells in solid tumors.

Monopteros operates under Series-A funding from Medicxi and holds exclusive patent licenses from the Massachusetts General Hospital and Helmholtz Zentrum München.

Monopteros Therapeutics
Contributions
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About UsNice InsightThat's Nice
Reach Our Team
Contact UsAdvertiseLinkedIn
My Account
LoginSign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy PolicyTerms And Conditions